AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Necrobiotic Xanthogranuloma: Diagnosis and Management

Description

The presentation focuses on necrobiotic xanthogranuloma (NXG), a non-infectious granulomatous skin disorder often associated with paraproteinemia and malignancies, particularly multiple myeloma. The pathogenesis of NXG remains unclear, although paraproteins and immune dysregulation play significant roles. The presentation highlights a multi-center cohort study of 235 patients which provides extensive demographic data, clinical features, and associations with paraproteinemia, revealing that 84% of patients had related malignancies. Clinical manifestations typically include periorbital involvement with yellow nodules or plaques, and can affect various organ systems, necessitating ophthalmological evaluation due to potential sight-threatening complications. The diagnosis is based on clinical features, biopsy results, and the presence of paraproteinemia. The presentation introduces validated diagnostic criteria established by consensus among dermatologists and discusses the diagnostic methodology, emphasizing the need for both major and minor criteria for accurate identification of NXG. In terms of treatment, while historical approaches included corticosteroids and chlorambucil, newer data indicate that intravenous immunoglobulin (IVIG) may offer the most effective response among various treatment options. Overall, careful monitoring is crucial given the high rate of malignancy associated with NXG.

View more

Conclusions

  • Necrobiotic Xanthogranuloma (NXG) is classified as a non-infectious granulomatous disorder and is a perineoplastic syndrome.
  • The pathogenesis of NXG is incompletely understood, often involving paraproteins that can disrupt macrophage function and promote inflammation.
  • NXG patients frequently exhibit paraproteinemia, with an 84% association with malignant conditions, particularly multiple myeloma.
  • The average age of NXG patients is around 62, with a predominantly female demographic.
  • Cutaneous lesions in NXG primarily present as yellow or orange papules, plaques, or nodules, with a significant incidence of periorbital involvement.
  • Histopathological features specific to NXG include palisading granulomas and inflammatory infiltrates, which are crucial for diagnosis.
  • Establishing diagnostic criteria through a Delphi consensus is effective for distinguishing NXG from other similar diseases, with high sensitivity and specificity.
  • Long-term monitoring for the evolution of paraproteinemia into multiple myeloma is critical, as it can occur several years post NXG diagnosis.
  • Treatment options for NXG are limited, but intravenous immunoglobulin (IVIG) shows promising response rates, alongside traditional therapies such as corticosteroids and chlorambucil.
  • Laboratory evaluations may reveal low HDL cholesterol, low complement C4 levels, and altered vitamin D metabolism, pointing to metabolic involvement in NXG.
  • Szalat R et al. Journal of internal medicine. 2014;276(3):269-284.
  • Szalat R et al. Blood. 2011 Oct 6;118(14):3777-84.
  • Guess R et al. J Clin Immunol. 2023 Dec 22;44(1):19.
  • Wood AJ et al. Arch Dermatol. 2009 Mar;145(3):279-84.
  • Bolognia JL, Schaffer JV, Cerroni L. Dermatology, 4th ed. Elsevier Saunders. 2018.
  • Nelson CA et al. JAMA Dermatol. 2020 Mar 1;156(3):270-279.
  • Ugurlu S et al. Am J Ophthalmol. 2000 May;129(5):651-7.
  • Higgins LS et al. Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):447-52.
  • Hilal T et al. Ann Hematol. 2018 Aug;97(8):1471-1479.
  • Finan MC and Winkelmann RK. J Cutan Pathol. 1987 Apr;14(2):92-9.
  • Kossard S, Winkelmann RK. Australas J Dermatol. 1980;21(2):85-88.
  • Bassir F et al. (unpublished data)
  • Shahriari N et al. JAAD Case Rep. 2022 Dec 15;32:41-43.
  • Henning C et al. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):e492-e495.
  • Steinhelfer L et al. Orphanet J Rare Dis. 2022 Mar 24;17(1):132.
  • Eltilib M et al. Clin Nucl Med. 2020 Dec;45(12):967-969.
  • Kim JG et al. Ann Dermatol. 2020 Feb;32(1):53-56.
  • Agarwal S et al. Cornea. 2014 Oct;33(10):1113-7.